SAB Biotherapeutics Inc Ordinary Shares SABS 深 沪
已收盘 10-17 16:00:00 美东时间
2.51
+0.340
+15.67%
华盛通- 最 高2.54
- 今 开2.25
- 成交量 44.75万股
- 最 低 2.10
- 昨 收 2.17
- 总市值 2613.19万
- 52周最高 6.60
- 市盈率 静 --
- 换手率 4.30%
- 52周最低 1.00
- 委 比 -95.76%
- 总股本 1041.11万
- 历史最高 129.00
- 量 比 2.70
- 振 幅 20.28%
- 历史最低 1.00
- 每 手 1
- 风险率 0.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多SAB Biotherapeutics Board Members Resign in Agreement
SAB Biotherapeutics ( ($SABS) ) has provided an announcement. On September 30, ...
10-01 04:59
SAB Biotherapeutics Approves Equity Plan Amendments
SAB Biotherapeutics ( ($SABS) ) has issued an announcement. On September 26, 20...
09-27 05:16
美股大行评级 | 潜在涨幅302.68%！Maxim Group上调T Stamp目标价至12美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持T Stamp"买入"评级，目标价从8美元升至12美元；Maxim Group：维持Rezolute"买入"评级，目标价从15美元升至20美元
09-22 18:44
SAB BIO Highlights Data in Multiple Presentations at EASD
SAB Biotherapeutics highlighted its Phase 2b SAFEGUARD study of SAB-142 for new-onset Stage 3 autoimmune type 1 diabetes (T1D) at the EASD Annual Meeting. Presentations emphasized SAB-142's multi-specific, potentially best-in-class immunomodulatory approach, which avoids sustained lymphodepletion unlike rabbit ATG. Data from Phase 1 studies demonstrated its safety and efficacy, with initial findings from INNODIA’s MELD-ATG trial supporting SAB-14...
09-19 11:24
美股大行评级 | Tigress Financial：维持苹果"强烈买入"评级，目标价升至305美元；杰富瑞维持百度"买入"评级，目标价升至157美元
今日重点评级关注：HC Wainwright & Co.：维持Astria Therapeutics"买入"评级，目标价从16美元升至20美元；HC Wainwright & Co.：维持Avalo Therapeutics"买入"评级，目标价从15美元升至25美元
09-18 10:13
Leerink Partners Initiates Coverage On SAB Biotherapeutics with Outperform Rating, Announces Price Target of $7
Leerink Partners initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Outperform rating and announces Price Target of $7.
09-17 20:20
SAB Biotherapeutics To Present At The 61st Annual Meeting Of The European Association For The Study Of Diabetes (Easd) Being Held September 15 – 19, 2025 At The Viecon - Vienna Congress & Convention Center In Vienna, Austria
MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a
09-04 04:18
SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes
SAB Biotherapeutics will present at the 61st EASD Annual Meeting in Vienna, Austria, from September 15–19, 2025, with four oral presentations and an INNODIA-hosted symposium. The sessions will focus on SAB-142, a fully human anti-thymocyte globulin for treating type 1 diabetes, discussing its mechanism of action, immunomodulation without lymphodepletion, pharmacokinetics, and specimen quality in clinical trials. Alexandra Kropotova and Christoph ...
09-03 20:05
Chardan Capital Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $12
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and lowers the price target from $20 to $12.
08-08 20:02
SAB Biotherapeutics Reports Increased Losses Amid Funding Boost
Sab Biotherapeutics, Inc. ( ($SABS) ) has released its Q2 earnings. Here is a b...
08-08 13:58
